Rybelsus for weight loss: what 25lbs actually means clinically

What did @davina_hart actually say?

Davina says she has lost 25 pounds in nine weeks on Rybelsus (oral semaglutide), eating the same breakfast and lunch every day totaling around 400 calories, plus a regular dinner. She describes this as easy, says she rarely snacks, and credits the medication with killing her appetite. She also mentions taking a daily multivitamin and notes she maintained her weight during a two-week all-inclusive holiday without tracking calories.

To her credit, she is not selling anything. She presents this as personal experience, not medical advice. But 171,000 views means this routine lands as a template for a lot of people who are probably eating similarly and wondering if they should be.

Does the science back this up?

The weight loss rate is plausible and supported by evidence. That said, the 400-calorie breakfast-plus-lunch pattern is genuinely risky territory, and a standard multivitamin does not fix it.

Semaglutide does suppress appetite significantly. The STEP 1 trial (Wilding et al., 2021, NEJM) showed average weight loss of around 15% body weight over 68 weeks in adults using injectable semaglutide 2.4mg. Oral semaglutide at lower doses produces more modest results, so 25 pounds in nine weeks is on the higher end, though not impossible, especially with caloric restriction this severe.

The problem is what happens at 400 calories before dinner. Research on very low calorie diets (VLCDs), generally defined as under 800 calories per day, consistently shows accelerated muscle loss alongside fat loss unless protein intake is adequate. Stunkard and colleagues, alongside more recent work by Heymsfield et al. (2011, American Journal of Clinical Nutrition), established that preserving lean mass on aggressive deficits requires structured protein targets, not just a meal replacement bar and a multivitamin.

What did they get wrong (or right)?

She got the appetite suppression piece right. GLP-1 receptor agonists genuinely reduce hunger, and that mechanism is well established. Her instinct to find a repeatable, low-decision eating structure also has some behavioral backing. Food monotony can reduce overall intake (Raynor and Epstein, 2001, Psychological Bulletin).

What she got wrong is assuming a multivitamin covers her nutritional bases on a sub-500 calorie first half of the day. It does not. Multivitamins do not contain adequate protein, essential fatty acids, or sufficient calories to prevent muscle catabolism. The meal replacement bar and breakfast she references are unnamed, so we cannot audit them, but the calorie figure she gives raises real questions about total protein across the day.

The bigger issue is that she describes this as eating "the same thing everyday" with no medical supervision mentioned, no blood work referenced, and no dietitian involvement. Rybelsus is a prescription medication. Using it alongside a near-VLCD without clinical oversight is not a cautionary tale she is telling. It is a routine she is recommending by example.

What should you actually know?

Oral semaglutide (Rybelsus) is FDA-approved for type 2 diabetes management. Its use for weight loss is off-label in the US, unlike injectable semaglutide (Wegovy). That distinction matters when you are combining it with aggressive calorie restriction and no apparent clinical guidance.

If your total calorie intake before dinner is 400 calories, you are almost certainly in VLCD territory depending on dinner size. VLCDs have a legitimate place in obesity medicine, but they are supposed to be medically supervised, with regular monitoring of electrolytes, lean mass, and micronutrient status. A general multivitamin is not a substitute for that monitoring.

The semaglutide shortage she mentions is real. FDA shortage lists have included semaglutide formulations on and off since 2022. What she does not address is what happens metabolically when GLP-1 therapy stops abruptly. Wilding et al. (2022, Diabetes, Obesity and Metabolism) showed significant weight regain after discontinuation, which makes her concern about next month more medically relevant than she may realize.

• Very low calorie eating on GLP-1 therapy without protein targets accelerates muscle loss.
• A standard multivitamin does not compensate for inadequate macronutrient intake.
• Rybelsus is approved for type 2 diabetes, not weight loss, in the US.
• Abrupt discontinuation of semaglutide is associated with meaningful weight regain.
• This eating pattern warrants dietitian involvement, not just a daily supplement.